Based on the Kalvista Pharmaceuticals Inc stock forecast from 4 analysts, the average analyst target price for Kalvista Pharmaceuticals Inc is USD 31.50 over the next 12 months. Kalvista Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Kalvista Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Kalvista Pharmaceuticals Inc’s stock price was USD 11.44. Kalvista Pharmaceuticals Inc’s stock price has changed by -2.56% over the past week, -3.46% over the past month and +39.51% over the last year.
No recent analyst target price found for Kalvista Pharmaceuticals Inc
No recent average analyst rating found for Kalvista Pharmaceuticals Inc
Company Overview Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts. Read Less
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule...Read More
Frequently Asked Questions About Kalvista Pharmaceuticals Inc (KALV) Stock
Based on ratings from 4 analysts Kalvista Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on KALV's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for KALV is USD 31.50 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 24.
Unfortunately we do not have enough data on KALV's stock to indicate if its overvalued.
The last closing price of KALV's stock was USD 11.44.
The most recent market capitalization for KALV is USD 0.50B.
Based on targets from 4 analysts, the average taret price for KALV is projected at USD 31.50 over the next 12 months.
This means that KALV's stock price may go up by +175.35% over the next 12 months.
We can't find any ETFs which contains Kalvista Pharmaceuticals Inc's stock.
As per our most recent records Kalvista Pharmaceuticals Inc has 118 Employees.
Kalvista Pharmaceuticals Inc's registered address is 55 Cambridge Parkway, Cambridge, MA, United States, 02142.
You can get more information about it from Kalvista Pharmaceuticals Inc's website at https://www.kalvista.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for KALV !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
